The Washington Post

@washingtonpost ↗

Deleted No

Hibernated Yes

Last Checked Feb. 12, 2023

Created

Thu Dec 29 19:03:02 +0000 2022

Likes

Retweets

Source

Twitter Web App

View Raw Data

JSON Data

View on Twitter

Likely Available

The Washington Post @washingtonpost

An investigation concluded that Biogen and the FDA ignored internal concerns and skirted the agency’s written guidance to allow the Alzheimer’s treatment Aduhelm to receive accelerated approval and hit the market at a cost to patients of $56,000 a year. https://t.co/7nvmPC8xOk — PolitiTweet.org

Posted Dec. 29, 2022 Hibernated

Preceded By

The Washington Post @washingtonpost

Breaking news: FDA, drug firm Biogen ignored internal concerns in approval of Alzheimer’s treatment, House panels say in scathing review https://t.co/lhRBvhUeZh — PolitiTweet.org

Posted Dec. 29, 2022 Hibernated

Followed By

The Washington Post @washingtonpost

The “unusual” collaboration unfolded through at least 115 meetings, calls and email exchanges between the company and the FDA in a year, said the report released Thursday by the Committees on Oversight and Reform, and Energy and Commerce. https://t.co/7nvmPC8xOk — PolitiTweet.org

Posted Dec. 29, 2022 Hibernated